Regulatory FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program FDAThe U.S.RegulatoryGene TherapyRead full story pharminent April 23, 2026 (Last updated: April 24, 2026) FDA The U.S. RegulatoryGene TherapyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug CoverageNext: FDA approves Regeneron’s hearing loss gene therapy Related Stories Regulatory Biogen’s salanersen gains FDA breakthrough therapy designation for SMA pharminent June 5, 2026 Regulatory Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars pharminent June 4, 2026 Regulatory FDA taps prior knowledge to expedite cell and gene therapy development pharminent June 3, 2026
